News Archive
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
Today's headlines include news about how House Republicans are eyeing the health law's prevention trust fund as a means to pay the cost of extending the current student loan interest rate for another year. House Majority Leader John Boehner, R-Ohio, has scheduled a Friday vote on this proposal.
Patient-reported improvements in vision after cataract surgery are high and are unrelated to the level of ocular comorbidity or whether the surgery is in the first or second eye, report researchers.
Taking a daily vitamin D supplement does not prevent type 2 diabetes in adults at high risk, according to results from a study funded by National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health.
A commonly prescribed diabetes drug, metformin, reduces the overall cancer risk in people with Type 2 diabetes, a large systematic review study finds. The results will be presented Monday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 2 days ago